AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 122 min read$OSCR

OSCR Maintained by UBS -- Price Target Raised to $36

UBS maintained a 'Neutral' rating for Oscar Health (OSCR) but raised its price target to $36 from $26. GuruFocus values OSCR at $24.66, suggesting it is 37.9% overvalued at $34.01. The company has a GF Score of 81/100, with strong growth and momentum but concerns over valuation and profitability. Insiders have sold $26.76M in shares over the past three months.

Original reporting
gurufocus.com
Published Oct 12, 2026, 9:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$OSCR
Neutral
high confidence
Mentioned
$OSCR
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$OSCRNeutralMed
01

Why it matters

UBS's price‑target raise suggests a modest upside, but high valuation and insider selling temper enthusiasm.

02

Market read

Analyst rating update provides a new data point for traders evaluating OSCR.

03

What to watch

Insider selling of $26.8 M could signal downside risk despite the higher target.

Relevance 7/10Novelty 5/10Timing: today

Background

Oscar Health (OSCR) is a U.S. health‑insurance provider with recent overvaluation concerns.

Company-level read

Ticker impact

$OSCRNeutralHigh confidence
Context

UBS maintained a Neutral rating on Oscar Health and raised its price target to $36, indicating a fresh analyst upgrade.

Expected impact

potential modest upside as the market prices in the higher target

Evidence & confidence

The new target reflects UBS's improved outlook, but the stock remains overvalued per GF metrics, limiting upside.

Market effects

Sector

The rating lift may slightly boost sentiment in the health‑insurance sector.

Regional

Limited to U.S. health‑insurance stocks.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The stock remains significantly overvalued; investors may view the upgrade as insufficient justification for buying.

Key entities

  • company
    Oscar Health

    U.S. health‑insurance provider

  • analyst
    UBS

    Maintained Neutral rating and raised price target

Read at source← All news

Related articles

SEP 16
$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

gurufocus.com2 min
SEP 16
$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

tipranks.com2 min
SEP 16
$OSCRHighAI 8/10

Oscar Health raises FY26 earnings guidance by $100 million

Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.

scanx.trade2 min